Immunocore publishes corporate presentation on bispecific soluble TCR platform and pipeline across oncology, infectious and autoimmune diseases - IMCR News | RalliesImmunocore publishes corporate presentation on bispecific soluble TCR platform and pipeline across oncology, infectious and autoimmune diseases
I
IMCR• Corporate presentation highlights KIMMTRAK sales and pipeline progress
- Immunocore highlighted KIMMTRAK as the standard of care in first-line metastatic uveal melanoma, reporting USD 223 million net sales in 1H 2026.
- Reported 16% year-over-year growth, citing USD 116 million net sales in Q2 2026.
- Commercial footprint expanded to more than 30 launched markets, with penetration of at least 70% across major launched markets.
- Pipeline focus centered on late-stage melanoma studies, with TEBE-AM enrollment nearing 540 patients, topline data as early as end-2026.
- Adjuvant uveal melanoma Phase 3 ATOM trial outlined at about 290 HLA-A02:01 patients, with primary endpoint relapse-free survival.
